Search

everythinglearnresearchcommunity

for

Search:↓

Disrupting Stat3 in hair follicle stem cells greatly reduces skin tumor formation.

Pygo2 is important for early growth and progression of intestinal tumors, and could be a target for treating cancers with certain mutations.

The extracellular matrix affects where tumors can start in the body.

Understanding phenotypic plasticity is crucial for developing effective cancer therapies.

YAP and TAZ proteins are necessary for the development of two types of skin cancer.

Wnt and Shh signaling are key in noggin-induced tumors, and blocking them can slow tumor growth.

Understanding where cancer cells come from helps create better prevention and treatment methods.

Cell death shapes skin stem cell environments, affecting inflammation, repair, and cancer.

Scientists made a mouse model of a serious skin cancer by changing skin cells with a virus and a specific gene, which is similar to the disease in humans.

Blocking YAP/TAZ could be a new way to treat skin cancer.

High lactate dehydrogenase activity is not necessary for the growth of squamous cell carcinoma.

Cells with active Wnt signaling are less likely to turn into cancer when exposed to a cancer-causing gene.

The document concludes that identifying the specific cells where skin cancers begin is important for creating better prevention, detection, and treatment methods.

The calcineurin/NFAT pathway plays a significant role in the development and growth of a type of skin cancer called cutaneous squamous cell carcinoma.

Different types of skin cells have unique genetic markers that affect how likely they are to spread cancer.

The tumor suppressor gene FLCN affects mitochondrial function and energy use in cells.

Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.

CYLD mutations cause a variety of skin tumors with symptoms starting around age 16, and treatments are currently limited.

Tumor cell adhesion is linked to higher risk of SLN metastasis and melanoma recurrence, and a model including these factors predicts these outcomes better than one with just clinical data.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Different types of stem cells exist within individual skin layers, and they can adapt to damage, transplantation, or tumor growth. These cells are regulated by their environment and genetic factors. Tumor growth is driven by expanding, genetically altered cells, not long-lived mutant stem cells. There's evidence of cancer stem cells in skin tumors. Other cells, bacteria, and genetic factors help maintain balance and contribute to disease progression. A method for growing mini organs from single cells has been developed.

Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.

Removing integrin α3β1 from hair stem cells lowers skin tumor growth by affecting CCN2 protein levels.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

LED light therapy at 863 nm wavelength can slow down skin tumor growth and reduce inflammation in mice.

Meis1 is crucial for skin health and tumor development.

Progesterone byproduct 5αP stimulates mammary tumor growth, but finasteride can suppress it.

Lacking cyclin D3 reduces skin cancer growth without affecting normal skin cell growth.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.